40.00
price down icon2.08%   -0.85
pre-market  Vorhandelsmarkt:  41.09   1.09   +2.73%
loading

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

pulisher
Jan 18, 2025

FY2024 EPS Estimates for RARE Boosted by Cantor Fitzgerald - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7%Should You Sell? - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jan 17, 2025
pulisher
Jan 17, 2025

Ultragenyx Awards 7,750 Restricted Stock Units to New Non-Executive Officers in Retention Plan - StockTitan

Jan 17, 2025
pulisher
Jan 17, 2025

Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential - Insider Monkey

Jan 17, 2025
pulisher
Jan 17, 2025

12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey

Jan 17, 2025
pulisher
Jan 17, 2025

FY2024 EPS Estimates for RARE Increased by Cantor Fitzgerald - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Trimmed by Hennion & Walsh Asset Management Inc. - MarketBeat

Jan 17, 2025
pulisher
Jan 16, 2025

Wealth Enhancement Advisory Services LLC Acquires 294 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World

Jan 16, 2025
pulisher
Jan 15, 2025

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside - AOL

Jan 15, 2025
pulisher
Jan 15, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 9.1%Here's Why - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $140.00 at Piper Sandler - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

Ultragenyx Pharmaceutical’s (RARE) “Neutral” Rating Reaffirmed at Wedbush - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use - MSN

Jan 14, 2025
pulisher
Jan 13, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Ultragenyx Pharmaceutical's (RARE) Neutral Rating Reaffirmed at Wedbush - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Ultragenyx stock gains confidence as FY25 guidance signals 14-20% growth - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

JPMorgan Chase & Co. Has $11.84 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World

Jan 13, 2025
pulisher
Jan 13, 2025

Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for 2024 -January 12, 2025 at 11:00 am EST - Marketscreener.com

Jan 13, 2025
pulisher
Jan 12, 2025

Mereo BioPharma Provides Update on Lead Clinical Programs - GlobeNewswire

Jan 12, 2025
pulisher
Jan 12, 2025

RAREUltragenyx Pharmaceutical Inc. Latest Stock News & Market Updates - StockTitan

Jan 12, 2025
pulisher
Jan 12, 2025

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones - GlobeNewswire

Jan 12, 2025
pulisher
Jan 12, 2025

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones - GlobeNewswire Inc.

Jan 12, 2025
pulisher
Jan 12, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $88.46 Consensus Target Price from Brokerages - Defense World

Jan 12, 2025
pulisher
Jan 09, 2025

Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder - MSN

Jan 09, 2025
pulisher
Jan 09, 2025

Hypophosphatasia Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | PuREC, AstraZeneca, Ultragenyx Pharma, Alexion - Barchart

Jan 09, 2025
pulisher
Jan 09, 2025

Hypophosphatasia Market Predicted to See Upsurge Through 2032, - openPR

Jan 09, 2025
pulisher
Jan 09, 2025

Ultragenyx Pharmaceutical's SWOT analysis: rare disease stock poised for growth - Investing.com Australia

Jan 09, 2025
pulisher
Jan 09, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

Ultragenyx Pharmaceutical's SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com South Africa

Jan 09, 2025
pulisher
Jan 09, 2025

Ultragenyx Pharmaceutical’s SWOT analysis: rare disease stock poised for growth - Investing.com Nigeria

Jan 09, 2025
pulisher
Jan 08, 2025

RBC Capital reiterates Outperform rating on Ultragenyx, optimistic on Osteogenesis Imperfecta drug - Investing.com Nigeria

Jan 08, 2025
pulisher
Jan 08, 2025

RBC Capital reiterates Outperform rating on Ultragenyx, optimistic on Osteogenesis Imperfecta drug By Investing.com - Investing.com South Africa

Jan 08, 2025
pulisher
Jan 08, 2025

Top 10 startups in Rare Diseases in Bay Area, United States in Jan, 2025 - Tracxn

Jan 08, 2025
pulisher
Jan 07, 2025

Political petulance, complacency halt pediatric priority review program - BioCentury

Jan 07, 2025
pulisher
Jan 07, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading 7.2% HigherTime to Buy? - MarketBeat

Jan 07, 2025
pulisher
Jan 06, 2025

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 06, 2025
pulisher
Jan 06, 2025

Ultragenyx CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 06, 2025
pulisher
Jan 06, 2025

European Commission (EC) Extends the Approval of Evkeeza® - GlobeNewswire

Jan 06, 2025
pulisher
Jan 06, 2025

Ultragenyx's Evkeeza Makes Breakthrough: First EU Treatment for Infant HoFH Patients - StockTitan

Jan 06, 2025
pulisher
Jan 03, 2025

Principal Financial Group Inc. Has $4.80 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Jan 03, 2025
pulisher
Jan 02, 2025

Ultragenyx asks FDA to review gene therapy for Sanfilippo A - Sanfilippo News

Jan 02, 2025
pulisher
Dec 31, 2024

Ultragenyx CEO Emil Kakkis sells $495,231 in company stock By Investing.com - Investing.com Canada

Dec 31, 2024
$30.75
price down icon 0.65%
$71.93
price down icon 0.75%
$19.03
price up icon 4.62%
$358.93
price down icon 2.04%
biotechnology ONC
$210.08
price up icon 2.31%
$111.93
price down icon 0.74%
Kapitalisierung:     |  Volumen (24h):